Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma

Diseases of the Esophagus

Volumn 27, Issue 4, 2014, Pages 380-387

  Blom, R L G M ^a   Sosef, M N ^b   Nap, M ^b   Lammering, G ^c   van den Berkmortel, F ^a   Hulshof, M C C M ^a   Meijer, S L ^a   Wilmink, H W ^a   Van Berge Henegouwen, M I ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Esophageal carcinoma; Esophagectomy; Neoadjuvant chemoradiotherapy; Pathological response; Survival; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LONG TERM SURVIVAL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADICAL RESECTION; THROMBOCYTOPENIA; VOCAL CORD PARALYSIS; ADENOCARCINOMA; ADJUVANT THERAPY; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RADIATION DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899491266     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12110     Document Type: Article

References (24)

1. Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83 (10): 2049-2053.
2. Pohl H, Welch H G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97 (2): 142-146.
3. Hulscher J B, van Sandick J W, de Boer A G etal. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347 (21): 1662-1669.
4. Law S, Fok M, Chow S, Chu K M, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114 (2): 210-217.
5. Sjoquist K M, Burmeister B H, Smithers B M etal. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12 (7): 681-692.
6. Ajani J A. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 2008; 113 (5): 945-955.
7. Minsky B D, Pajak T F, Ginsberg R J etal. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20 (5): 1167-1174.
8. van Hagen P, Hulshof M C, van Lanschot J J etal. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366 (22): 2074-2084.
9. van Heijl M, van Lanschot J J, Koppert L B etal. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008; 8: 21.
10. Trotti A, Colevas A D, Setser A etal. CTCAE V3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13 (3): 176-181.
11. Sobin L H, Wittekind C. International Union against Cancer. TNM: Classification of Malignant Tumours. New York: Wiley-Liss (NYC), 2002.
12. Chirieac L R, Swisher S G, Ajani J A etal. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103 (7): 1347-1355.
13. Ancona E, Ruol A, Santi S etal. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91 (11): 2165-2174.
14. Burmeister B H, Smithers B M, Gebski V etal. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6 (9): 659-668.
15. Burmeister B H, Thomas J M, Burmeister E A etal. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47 (3): 354-360.
16. Cunningham D, Allum W H, Stenning S P etal. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (1): 11-20.
17. Walsh T N, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335 (7): 462-467.
18. Ychou M, Boige V, Pignon J P etal. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29 (13): 1715-1721.
19. Herskovic A, Martz K, al-Sarraf M etal. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326 (24): 1593-1598.
20. van Meerten E, Muller K, Tilanus H W etal. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006; 94 (10): 1389-1394.
21. Bosset J F, Gignoux M, Triboulet J P etal. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337 (3): 161-167.
22. Lee J L, Park S I, Kim S B etal. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15 (6): 947-954.
23. Stahl M, Walz M K, Stuschke M etal. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27 (6): 851-856.
24. Gebski V, Burmeister B, Smithers B M, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8 (3): 226-234.